title: Adjuvant therapy of melanoma patients (stage II, III): a pilot immuno-toxicological study.
abstract: A pilot study was conducted to assess the tolerability and the effect on host immunity of a post-surgery adjuvant treatment of melanoma patients with an anti-angiogenic agent, Tamoxifen (TAM, 20 mg/die p.o., daily), combined with immunomodulating cytokines, i.e. recombinant interleukin-2 (IL-2, 4 MUI/m2 s.c., day 8,10,12) and alpha-2b-interferon (IFN, 3 MUI/m2 i.m., day 15,17,19), starting a new cycle on day 21, for a total of 12 cycles. Fifty patients (pts) entered into the study, 27 males and 23 females with a median age of 55 years (range 25-75), performance status (ECOG) 0 with melanoma stage IIA (12 patients), stage IIB (28 patients), stage III (10 patients). Preliminary in vitro studies showed that TAM does not interfere with up-regulation of natural immunity induced by IFN, IL-2, or IFN + IL-2 in normal peripheral blood mononuclear cells (MNC). The clinical study indicates that the protocol was well tolerated. Increase of NK and LAK activity of patient MNC was observed on day 15. The mean disease-free interval was 10 months and 40 pts were alive at 5 years of follow-up. Further investigations should be performed to test effectiveness of this protocol in a randomized study.
authors.affiliation: Inst. of Neurobiology and Molecular Medicine, National Research Council, Rome, Italy. maria.tricarico@ims.rm.cnr.it
authors.forename: M
authors.initials: M
authors.lastname: Tricarico
authors.forename: C
authors.initials: C
authors.lastname: Nunziata
authors.forename: F
authors.initials: F
authors.lastname: Atzori
authors.forename: F
authors.initials: F
authors.lastname: Concolino
authors.forename: V
authors.initials: V
authors.lastname: Macchini
authors.forename: S
authors.initials: S
authors.lastname: D'Atri
authors.forename: S P
authors.initials: SP
authors.lastname: Prete
authors.forename: M
authors.initials: M
authors.lastname: Turriziani
authors.forename: G
authors.initials: G
authors.lastname: Lanzilli
authors.forename: F
authors.initials: F
authors.lastname: Sera
authors.forename: D
authors.initials: D
authors.lastname: Abeni
authors.forename: V
authors.initials: V
authors.lastname: Albanesi
authors.forename: E
authors.initials: E
authors.lastname: Bonmassar
authors.forename: E
authors.initials: E
authors.lastname: Pagani
mesh_terms: D000328:Adult; D000368:Aged; D002460:Cell Line; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000378:metabolism; D007372:Interferons / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D007694:Killer Cells, Natural; D007700:Kinetics; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D010865:Pilot Projects; D011897:Random Allocation; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000378:metabolism; D013629:Tamoxifen / Q000494:pharmacology*; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D013629:Tamoxifen; D007372:Interferons